Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients

This study has been completed.
Prof. Philip Halloran, Edmonton, Canada (sponsor)
Prof. Yves Vanrenterghem, Leuven, Belgium (Steering Committee Member)
Prof. Pierre Daloze, Montréal, Canada (Steering Committee Member)
Prof. Thomas C. Pearson, Atlanta, USA (Steering Committee Member)
Prof. Ulrich Frei, Berlin, Germany (Steering Committee Member)
Prof. Flavio Vincenti, San Francisco, USA (Ass. Steering Committee Member)
Prof. Josep Grinyo, Barcelona, Spain (Ass. Steering Committee Member)
Hoffmann-La Roche
Information provided by:
Ekberg, Henrik, M.D. Identifier:
First received: September 30, 2005
Last updated: April 22, 2008
Last verified: April 2008
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2008
  Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):